FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

SILVER SPRING, Md., May 11, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in...